US Patent Issued to DAIICHI SANKYO on June 30 for "Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate" (Japanese Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,667,557, issued on June 30, was assigned to DAIICHI SANKYO COMPANY Ltd. (Tokyo).

"Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate" was invented by Kimio Yonesaka (Osaka-Sayama, Japan), Kazuhiko Nakagawa (Osaka-Sayama, Japan) and Kenji Hirotani (Tokyo).

According to the abstract* released by the U.S. Patent & Trademark Office: "[Problem] To provide a therapeutic agent and a therapeutic method for EGFR-TKI-resistant non-small cell lung cancer.[Solution] Provided are: a therapeutic agent that contains an anti-HER3 antibody-drug conjugate as an active ingredient, or a therapeutic method characterized by administerin...